HD-OPM Archive
Hashtags

#zeus

4 posts

Pelacarsen and ziltivekimab lowered their targets but not events, and why that matters

Nov 08, 2026 · Louis Nervegna ♥ 8 · 💬 6 Lp(a)

Louis shares a physician's commentary on the Lp(a) and inflammation trials presented at AHA: one drug lowered Lp(a) nearly 80% and another sharply cut inflammation, yet event rates matched placebo. The lesson is that measuring and changing a marker does not guarantee benefit, and that the underlying risk factors still matter.

Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events

Nov 13, 2026 · Louis Nervegna ♥ 3 · 💬 1 Lp(a)

Shared summary of two NEJM trials. Pelacarsen lowered Lp(a) sharply but event rates were 12.3% vs 12.1% on placebo, and ziltivekimab cut CRP and IL-6 but events were 17.6% vs 17.7%. The post notes prior biomarker failures (torcetrapib, dalcetrapib), and that both trials enrolled people with existing disease and so do not prove Lp(a) or inflammation are not causal.